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Lungs are no longer considered sterile
and their microbiota are associated with
lung wellness.
The lung microbiome has been linked to
lung carcinogenesis and establishment
of lung metastasis from other primary
cancers.
Lung microbiota dysbiosis may modu-
late the risk of malignancy at multiple
levels including chronic inflammationMicrobiota have emerged as key modulators of both the carcinogenic process
and the immune response against cancer cells, and, thus, it seems to influence
the efficacy of immunotherapy. While most studies have focused on analyzing
the influence of gut microbiota, its composition substantially differs from that in
the lung. Here, we describe how microbial life in the lungs is associated with
host immune status in the lungs and, thus, how the identification of the microbial
populations in the lower respiratory tract rather than in the gut might be key to
understanding the lung carcinogenic process and to predict the efficacy of
different treatments. Understanding the influence of lung microbiota on host
immunity may identify new therapeutic targets and help to design new immuno-
therapy approaches to treat lung cancer.and oncogenes.
Patients treated with antibiotics before/
during immunotherapy present with
significantly lower progression-free sur-
vival and overall survival rates compared
with patients who have not received
antibiotics.
Profiling of the gut microbiota revealed
dysbiotic signatures associated with
delayed tumor outgrowth and favorable
responses to immunotherapy.
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The relationship between microbiota (Box 1) and cancer is currently under intensive investigation.
Although microbiota are composed of bacteria, archaea, protists, fungi, and viruses, most stud-
ies addressing the influence of microbiota on cancer have focused on bacterial microbiota, and
thus we also focus on bacteria. A large number of studies providing insights on how bacteria
and abnormal growth of mammalian cells are related have been conducted. Bacteria may disrupt
the cell cycle by toxin production, resulting in cell growth with alterations in protein expression that
control DNA repair, cell division, and apoptosis [1,2]. Furthermore, bacteria may alter the host
immune response against malignant cells, and an association between microbiota composition
and clinical immunotherapy response has recently been shown. Studies in animalmodels indicate
that microbiota modulate the sensitivity of solid cancers to immune checkpoint inhibitors (ICIs),
mainly cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death-1
(PD-1)/ligand 1(L1) [3–5]. The best characterized microbiome–cancer relationship is between
gut microbiota and gastrointestinal and metabolic diseases such as gastric cancer [6], inflamma-
tory bowel disease [7] (a risk factor for colorectal cancer), diabetes, and obesity [7–9]. The rela-
tionship between gut-related pathogenesis and microbiota is not surprising since the gut is the
main tissue colonized by the commensal microorganisms, which comprise 3.93 × 1013 bacteria.
However, during recent years it has been found that other healthy organs and tissues also contain
significant numbers of microorganisms, such as the lower respiratory tract. Thus, the principles
of respiratory microbiology are being studied again, starting with the lung sterility myth [10]. For
example, the association between oral microbiota and risk of lung cancer has been reported
[11]. Lung cancer is currently one of the most common causes of cancer death worldwide in
both men and women. The 5-year survival rate of lung cancer patients is b20% [12]. Thus, under-
standing how the microorganisms present in the respiratory tract might influence lung carcinoma
development and treatment efficacy could be key in predicting the risk of cancer developmentTrends in Cancer, Month 2020, Vol. xx, No. xx https://doi.org/10.1016/j.trecan.2019.12.007 1
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Table 1. Bacterial Communities Detected in Lung Cancer Patients
Taxa features Sample numbers Sample type Refs
Granulicatella
Abiotrophia
Streptococcus
16 Sputum samples [35]
Granulicatella
Streptococcus
Mycobacterium
10 Sputum samples [38]
Veillonella
Megasphaera
28 Bronchoalveolar lavage [37]
Cyanobacteria 29 Lung tissue [1]
Streptococcus
Neisseria
42 Protected bronchial brushing [15]
Streptococcus
Prevotella
40 Lung tissue [36]
Acidovorax 176 Lung tissue [17]
Streptococcus
Veillonella
85 Airway brushes [32]
Box 1. Microbiota and Microbiome
The termmicrobiota refers to the ensemble of microorganisms (bacteria, archaea, fungi, viruses, and protozoa) that reside
in an individual at a given time, whereas the total genome of these microorganisms is designated as the microbiome
[70,71]. Microorganisms are found inmany parts of the human body, primarily on the external and internal surfaces, includ-
ing the gastrointestinal tracts, saliva, oral and genital mucosa, lung, bladder, skin, and conjunctiva. The human microbiota
is primarily colonized by Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, and Cyanobacteria
[1,72–74]. Currently, it has been estimated that a ratio of bacteria to human cells in the body is close to 1:1 [75].
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eva@icb.csic.es (E.M. Gálvez).and to improve treatment efficacy and safety. The human body is teeming with microbes, but
the composition of the microbiota differs by anatomical site, such as the oral and nasal cavities
(interconnected to the lung and the stomach via the pharynx and esophagus, respectively)
colon, vagina, and skin. Cooperative interactions between microbiota and host might involve
microbial participation in host functions such as defense and metabolism. Thus, the same micro-
organisms that are beneficial to human health, under certain circumstances, might promote
disease and cancer development. In other cases, changes in the composition of microbiota
might lead to disease. (See Table 1.)
In this review, we summarize the current scientific knowledge to gain a deeper insight into how the
lung microbiota composition and function may affect lung cancer development. We discuss how
lung microbiota changes could alter host–microbiota interactions by modulating the healthy and
pathological immune response and how this modulation offers new alternatives for successful
and safe immunotherapy in lung cancer.
Lung Microbiota
Viable and Nonviable Components of Lung Microbiota
The lungs are constantly exposed to microorganisms present in the upper respiratory
airways and suspended in the air. Nevertheless, until recently, the healthy lungs were considered
to be sterile organs since bacteria were rarely isolated from normal healthy lungs using
conventional culture techniques. However, although bacterial biomass in human lungs is low
(5–8.25 log copies/ml) [13,14], nowadays bacterial DNA is commonly found in the lower respira-
tory tract, where it has been detected in healthy individuals thanks to next-generation sequencing
Box 2. Molecular Methods to Characterize the Lung Microbiota
NGS has emerged as a potent technology for the molecular characterization of microorganisms in complex samples.
According to the desired microbial kingdom to be characterized, bacteria, archaea, or fungi, specific primers against
genomic regions conserved within every kingdom are selected. Primers against the 16S rRNA, 18S rRNA, or internal tran-
scribed spacer (ITS)1/ITS2 regions and V4/V9 regions in 18S rRNA are selected for bacteria/archaea, fungi, and protists,
respectively. In the case of viruses, purification of virus-like particles followed by shotgun technology is preferred [76].
By far, 16S rRNA sequencing is the most advanced technology and has been key to identify the prokaryotic (bacteria and
archaea) microbial composition of complex samples. However, it still presents some limitations, such as its inability to
differentiate between species with varying immunogenicity and pathogenicity. 16S rRNA sequencing only provides infor-
mation at the genus level and does not differentiate species since this technology is based on short read lengths, which
makes precise taxonomic assignment difficult. This challenge potentially explains why the most robust associations that
have been observed between bacterial species and the human gut concern species that are unique in humans among
their genus [77–79]. An alternative to directed NGS, is whole genome sequencing, which may be even more informative
[80]. All these recent developments have enabled identification beyond the species level, but only for dominating popula-
tions. Major advances in bioinformatics and combination of culture-dependent and -independent methods like matrix-
assisted laser desorption/ionization (MALDI)-TOF (time of flight) mass spectrometry and 16S rRNA sequencing has en-
abled the analysis of entire sequence data sets using similarity algorithms or clustering tools without taxonomic assignment
[79,81,82]. This has allowed the discovery of unknown bacteria [79] and the isolation of hundreds of new bacterial species
in less than 5 years. Despite all these advances in molecular identification and diagnosis, it is worth noting that culture-
independent methods are not always more sensitive than traditional culture methods for the identification of bacterial
species. For example, 16S rRNA sequencing has shown lower performance than culture in the identification of species
within the Mycobacterium genus [83]. Thus, it seems that a combination of molecular culture-independent methods with
culture might be the best option for reliable characterization of bacterial populations and microbiota.
Trends in Cancer(NGS) technologies (see Box 2) [13,15–18]. It should be noted that different studies suggest that
most bacterial DNA detected in the lungsmight come from nonviable bacteria. Indeed it has been
found that more than 90% of microbial DNA was DNase I sensitive, indicating that this DNA orig-
inated from nonviable microorganisms [16,19]. Willis et al. also found that up to 50% of the bac-
terial DNA from sinus tissue was derived from nonviable sources [20]. The traditional view that
viable bacteria are rarely present in normal healthy lungs is consistent with the lungs being actively
surveilled by immune cells and the observation that 30% of tissue samples were sterile in the
Scheiermann and Klinman study [16]. In line with these findings, Segal et al. reported that the bac-
terial DNA content in some human lung samples could not be distinguished from that of back-
ground/negative control samples [18]. These findings supported the conclusion that most of
the bacterial DNA isolated from lung tissue derives from dead/nonviable organisms. Bacterial
DNA could be biologically relevant in shaping the lung immune system since CpG motifs present
in bacterial DNA can activate the innate immune system via Toll-like receptors [21,22] or other
pathogen recognition receptors found in alveolar macrophages and bronchial and alveolar epi-
thelial cells [22,23]. In contrast to the findings mentioned above, independent studies have re-
ported that the microbes present in the lower respiratory tract can be cultured when
appropriate protocols are utilized, indicating that this microbiome is not simply composed of bac-
terial DNA or debris [24,25].
Initial Establishment of Lung Microbiota
Studies in animal models have demonstrated that bacterial load in the lungs increases over
the first 2 weeks of life, and the taxa of organisms detected in the lung change from
Gammaproteobacteria and Firmicutes to Bacteriodetes [26]. Such microbiota changes are
thought to be associated with accumulation of a PD-L1-dependent T regulatory cell population
that promotes tolerance to environmental allergens [26]. Therefore, the lung microbiota would
be a key early life event required to shape the lung immune system and protect the organ from
injurious inflammatory responses to inhaled antigens. This early process might promote
commensal microbiota tolerance, avoiding inflammation-related lung damage and, likely, lungTrends in Cancer, Month 2020, Vol. xx, No. xx 3
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Figure 1. Relationship between Lung Microbiota, Homeostasis, and Lung Cancer. There is a delicate equilibrium between the immune system and microbiota.
The commensal microbiota contributes to immune tolerance, decreasing lung inflammation through dendritic cell (DC), γδ T, and T regulatory (Treg) cell recruitment.
Macrophages and T cells respond to microbial colonization and prevent the overload of pathogens or metabolites (left panel). Lung microbiota might contribute to lung
cancer development. Bacteria might promote proinflammatory factors leading to chronic inflammation and upregulation of proliferative signaling pathways in airway
epithelial cells inducing cell transformation and tumorigenesis (right panel). In addition, some microbial components might directly affect protumorigenic pathways in
epithelial cells (oncogenes). Abbreviations: iNKT cell, invariant natural killer cell; Th1/17, T helper type 1/17.
Trends in Cancercarcinogenesis (Figure 1). In humans, it has been recently shown that the microbial communities
in the lower airways are acquired within the first 2 months of life [27]. Lungmicrobiota composition
depends on the delivery method in preterm but not term infants. Thus, these data suggest that
diseases related to lung microbiota composition such as cancer might be influenced by the
duration of pregnancy, although this hypothesis requires validation. Nevertheless, similar to the
upper respiratory tract and gut, it is likely that the bacterial communities in the lung are dynamic
[28,29], since the airways are constantly exposed to air that flows through the upper respiratory
tract and oral cavity. Thus, in healthy individuals, it is not clear to what extent the deep airways are
stably colonized by specific microbial communities, or whether the microbes are in a dynamic4 Trends in Cancer, Month 2020, Vol. xx, No. xx
Trends in Cancerstate of flux being constantly cleared and repopulated, most likely from the upper respiratory
tract. At least, under healthy conditions, it seems that there is constant seeding and turnover of
the lower respiratory tract microbiota, which can be characterized by both culture-dependent
and -independent methods [30].
Microbiota Composition of Healthy Lungs
Themicrobial composition in healthy lungs analyzed by culture-independent techniques seems to
be enriched in the phyla Bacteroidetes and Firmicutes [18,31]. It was found that oral commensals
like Prevotella, Veillonella, and Streptococcus are present in the lungs from most healthy individ-
uals [13,15,18,31,32]. Microaspiration of pharyngeal secretions in healthy subjects seems to be
the main source of the lung microbiome [2–5]. However, these genera might not be present in all
healthy individuals as it has been shown that the lung microbiome can be classified according to
the bacterial load and taxa in two groups called pneumotypes. The first group has a high bacterial
load and is enriched with oral microorganisms such as Prevotella and Veillonella, and is known as
the supraglotic predominant taxa (SPT) pneumotype. The second group has a low bacterial load
and background environmental taxa such as Acidocella and Pseudomonas, and is known as the
background predominant taxa (BPT) pneumotype [18]. While individuals exhibit some spatial
variation in the microbiota of their respiratory tract, intrasubject variation is significantly less than
that of intersubject variation [13].
It has been shown that the bacteriome enriched in oral commensals (SPT) correlates with T helper
17 cells (Th17)-related local inflammatory response, which seems to be key in modulation of lung
immune status in health and disease (Figure 1) [33]. It will be interesting to find out whether indi-
viduals with the STP pneumotype present with a higher or lower risk of lung cancer or if changes
from the BTP to STP pneumotype affect the risk of lung cancer development and/or the efficacy
of treatment. This is not a trivial question since the correlation between Th17 response and cancer
is not clear yet, as discussed later.
Another study of nonmalignant lung tissue indicated that the lung microbiota differ from those of
the oral cavity and other sites and are dominated by Proteobacteria (60%) [34].
Microbiota Composition in Lung Carcinoma
Concerning the lung microbiota in lung cancer patients, although few studies have been per-
formed, a significant enrichment of Granulicatella, Abiotrophia, and Streptococcus at genus
level and decreased community diversity have been observed in patient compared with control
samples [15,34–38]. The difference in the bacterial communities between healthy individuals
and lung cancer patients might serve as a screening tool to predict lung cancer development
using bronchoalveolar fluid. Liu et al. have provided evidence that lung-cancer-associated micro-
biota are enriched in Streptococcus while depleted in Staphylococcus, which suggests a delete-
rious role of Streptococcus and protective role of Staphylococcus in the development of lung
cancer [15]. This hypothesis contrasts with other findings about the role of these taxa in carcino-
genesis, since it has been shown that Staphylococcus has the ability to induce DNA damage
while Streptococcusmay play a role in its prevention [39]. However, these apparent contradictory
findings could be explained by the difficulties in identifying actual species or strains involved in
carcinogenesis. By contrast, certain taxa might play distinct roles at different body niches or
even the same taxa can have protective or detrimental functions at the same place depending
on the presence of different stimuli.
It should be considered that the lung microbiota composition are associated with lifestyle, pollu-
tion, tobacco smoke, and coal burning, and these factors might have contributed to the differentTrends in Cancer, Month 2020, Vol. xx, No. xx 5
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has been shown that the genus Thermus is more abundant in tissue from advanced stage cancer
patients, while Legionella is more abundant in people who develop metastases [34]. However,
more and larger studies, both in animal models and patient lung tissues, are necessary to validate
these findings, and to gain deeper knowledge of the composition of lung microbiota and their role
in lung cancer, before they can be used as cancer biomarkers or included in therapeutic
approaches.
Microbiota Composition Modulates Chronic Inflammation and Cancer
Development
The lung microbiome has received less attention than the gut microbiome, and, by contrast to
gastrointestinal cancer, the correlation between microbiota and lung cancer has been less stud-
ied. However, even though there are fewer studies, the composition of the lung microbiota has
recently been associated with lung cancer. Adenocarcinoma and squamous cell carcinoma are
the major forms of non-small cell lung cancer (NSCLC). Even when smoking is correlated with
its etiology, it alone cannot completely explain lung cancer incidence. Some authors have hypoth-
esized that altered lungmicrobiome and chronic inflammation in lung tissue contribute to carcino-
genesis [1,17]. In this regard, the correlation between repeated antibiotic exposure and increased
risk of lung cancer has been studied. Although there is epidemiological evidence pointing out this
relationship, the contribution of the lung microbiome to lung cancer is still unknown [40]. It is well
known that chronic inflammation is a risk for cancer development, including lung cancer [41], and
this relationship has been the focus of most studies linking microbiota and lung carcinogenesis,
as discussed in detail in the next section. Several bacteria have been associated with chronic
inflammation and subsequent increased cancer risk. For example, Mycobacterium tuberculosis
has been associated with lung cancer [42], Bacteroides fragilis and Fusobacterium nucleatum
to colon cancer, and Helicobacter pylori to gastric cancer.
Bacterial Products Might Promote Host Oncogene Activation
Some microbial components might directly activate molecular pathways with oncogenic poten-
tial. Although few microbes have been identified as carcinogenic per se, with the notable excep-
tion of some oncoviruses, recent work has identified some relationships between changes in the
lung tissue microenvironment and microbial colonization that might affect cell transformation and
carcinogenesis. Greathouse et al. hypothesized that the interplay between smoking, TP53, and
microbiota might be relevant during smoking-driven lung carcinogenesis. Lung epithelial cells
with mutations in TP53 due to tobacco smoke are invaded by species that take advantage of
the new microenvironment, suggesting that these bacteria could act as promoters in lung tumor-
igenesis [17]. Another study showed that ERK and phosphoinositide 3-kinase (PI3K) signaling
pathways are upregulated in vivo and in vitro after exposure of airway epithelial cells to Veillonella,
Prevotella, andStreptococcus [32]. PI3K is a key pathway involved in the pathogenesis of NSCLC
since it regulates cell proliferation and survival [2,43]. Apopa et al. found that CD36 could act as
the connection between lung microbiota and specific insults that contribute to lung cancer devel-
opment [1]. Altered expression of CD36 in lung tissue is associated with lung cancer [44–46].
CD36 has been shown to interact with pathogen-derived ligands or toxins [47,48] and it is an
important mediator of inflammatory pathways [49]. However, they showed that CD36 might
modulate lung carcinogenesis by affecting the poly (ADP-ribose) polymerase 1 (PARP1) pathway
[49] that is an important regulator of cell proliferation and carcinogenesis. It was found that CD36
regulates the internalization and processing of Cyanobacteria-derived microcystin residues in the
lung alveoli, increasing PARP1 expression [1]. They detected, in addition to Bacteriodetes and
Proteobacteria as the most predominant phyla, Cyanobacteria (0.53%) in patient lung samples,
supporting the relevance of the mechanism described.6 Trends in Cancer, Month 2020, Vol. xx, No. xx
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Microbiota Shapes a Healthy Lung Immune System
Lung microbiota are thought to provide resistance to colonization by respiratory pathogens and
to play a key role in the regulation of immune tolerance in the lung microenvironment (Box 3).
In addition, they are considered integral to the development and training of the human immune
system. It is likely that the relationship between our pulmonary immune system and themicrobiota
is dynamic and this relationship likely changes with age and environmental exposures, in line
with the dynamic changes observed for the lung microbial communities as mentioned earlier.
The coevolution of the host immunity–microbiota interaction is likely to be responsible for the
development of regulatory pathways that modulate self-tolerance and tolerance against
nondangerous agents versus elimination of pathogens and tumor cells [50].
In the lungs, γδ T cells are thought to be important effector and regulator cells in host innate
immune responses to pulmonary infections, and their precise role seems to be pathogen
dependent [51]. Inhalation of innocuous bacteria, which do not result in a bacterial dysbiosis or
infection, has been shown to promote recruitment of γδ T cells and protect against airways
hyper-responsiveness. In addition, γδ T cells appear to have a protective effect against allergy
(Figure 1) [52–54]. Remot et al. have also shown that colonization of the neonatal airways with
specific bacterial strains protects against exaggerated allergic airway inflammation [24]. Data
from experimental models have confirmed that microbial components can protect mice against
allergic airway inflammation developing tolerance to aeroallergens [26,55]. These and other
works suggest that microbial exposure throughout childhood is required for the generation of a
healthy fully competent lung immune system [26,52,54–57]. Invariant natural killer (iNK) T cells
and PD-L1-tolerogenic pathways on dendritic cells (DCs), which regulates the induction of
peripheral regulatory T (Treg) cells, seem to be the critical cellular mechanisms that modulate
these processes (Figure 1).Box 3. Lung Immunity
The upper and lower respiratory tracts are critical sites where the host immune system must respond against potentially
harmful agents, differentiating them from self-components, foreign nondangerous material, and beneficial commensal
microbiota. Among the intricate organization of local immune cells responsible for maintaining lung homeostasis, the
epithelium–macrophage axis is a key part that facilitates maintenance of the steady state. The pulmonary epithelium
is a barrier that provides a vital line of host defense against pathogenic microorganisms. Within the epithelium, ciliated
columnar, mucus secreting goblet cells, tuft cells, and Club cells form a regulated, impermeable barrier. The airway
epithelial layer has another protective feature which is mucociliary action [84,85].
Although epithelial cells and macrophages make-up the first line of defense of the airways, there is a second line,
consisting of tissue-resident lymphoid cells. This resident population is mainly formed by γδ T cells, NKT cells, innate lym-
phoid cells (ILCs), and specific subsets of memory B and T cells, the resident memory B and T cells. When an antigen is
encountered in the lungs, together with resident memory cells, specialized subsets of T and/or B cells are activated in
draining lymph nodes and recruited to the lung to participate in the elimination of the offending insult.
Activation of the adaptive immune response is regulated by an integrated network of DCs that can roughly be divided into
two subsets, the CD11b+CD103- and CD11b-CD103+ DCs [86–88]. Macrophages and DCs are some of the most critical
determinants of the immunological tone of the airways.
Lung-resident memory T cells, characterized by expression of CD4, CD8, CD69, and a diverse T cell receptor repertoire,
form an important component of adaptive immunity at barrier surfaces and provide rapid immune responses in healthy
lungs [89–91]. The presence of different ILC subsets is enhanced at barrier surfaces and they are thought to play a key
role for maintenance of homeostasis, and regulation of immunity and tissue repair [92]. In the same way, Treg cells are
resident cells within lungs and are vital for maintenance of immune tolerance to airborne particles by a PD-L1-dependent
mechanism [93]. Accumulating evidence shows that these resident pulmonary Treg cells are present from birth and
their phenotype is directly influenced by the local microbiota [26]. γδ T cells constitute a major T cell component of
mucosal epithelial barrier tissues where they can respond to danger signals and facilitate orchestration of immune
responses [94,95].
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The delicate balance between tolerance and lung immune activation can be disrupted by
changes in the host immunity–microbiota partnership by the overuse of antibiotics, changes
in diet, or chronic infections, which might increase the risk of lung cancer [58]. The potential
increased risk of lung cancer due to changes in microbiota could be related to either hyper-
responsive immunity leading to chronic inflammation as described in the previous section
(Figure 1) or defective immunosurveillance mechanisms (Figure 2).Trends in Cancer
Figure 2. Potential Immunomodulatory Approaches to Revert the Protumoral Immune Microenvironment Due to Lung Microbiota Dysbiosis. Red lines:
tumor development shapes an immunosuppressive microenvironment enriched in T regulatory (Treg) cells and M2 macrophages expressing anti-inflammatory
molecules such as programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), or transforming growth factor TGF-β. These
factors inhibit antitumoral natural killer (NK) and T cell responses, promoting tolerance and tumor immune evasion. Lung microbiota dysbiosis and the presence of
specific bacterial strains might contribute to the generation of this immunosuppressive microenvironment and the low efficacy of immunotherapy treatments.
Green arrows: immunotherapy treatments such as immune checkpoint inhibitors (ICIs) in combination with strategies to modulate lung microbiota (bacterial
aerosols and/or selective antibiotic treatments) might help to revert dysbiosis and enhance antitumoral host immune responses. Abbreviations: DCs, dendritic
cells; PD-1, programmed cell death-1.
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bacteria in supporting the host immune response against cancer, revealing a defective induction
of lung immunity after antibiotic treatment [59]. Notably, in the same way that healthy microbiota
modulate tolerance and are beneficial to prevent allergic reactions, under some circumstances,
they might create a permissive environment for cancer. For example, some bacteria might help
cancer cells to colonize lung tissue and establish lung metastases. Le Noci et al. found that
local antibiotic treatment reduces the implantation of experimental lungmetastases and this effect
is associated with the modulation of the immune response [60]. Thus, these aspects should
be carefully considered before any treatment using different bacteria strains are implemented in
clinical settings.
An exacerbated immune response might lead to chronic inflammation and cancer development.
The immune response induced by microbiota would be beneficial or deleterious to cancer
patients, likely depending on the specific types of responses activated and the specific types of
bacteria involved (Figures 1 and 2). For example, bacteria-driven immune activation may exacer-
bate tumorigenic inflammation (Figure 1). Ma et al. found that NSCLC patients presented signifi-
cantly higher frequencies of T helper type 1 (Th1) and Th17 cells reacting to Streptococcus
salivarius and Streptococcus agalactiae compared with healthy controls [61]. Importantly, lung
inflammation mediated by Th17 cells has been identified as an important factor in the initiation
and metastasis of lung cancer [61,62]. However, this finding should be interpreted with caution
since it has been shown that Th17-mediated neutrophil responses either promote carcinogenesis
or, in contrast, can protect from cancer development and contribute to treatment efficacy [63,64].
Notably, γδ T cells have been recently found to contribute to lung cancer development after
enhanced activation and proliferation mediated by commensal lung microorganisms [65]. The
amount of lung bacterial load is directly linked to lung cancer development due to enhanced
inflammation. This process is mediated by myeloid cells that enhance γδ T cell activation and
proliferation (Figure 1) [65,66]. In contrast to carcinogenic inflammatory immunity, specific CD8+
T cell-dependent inflammation toward certain bacterial strains has been demonstrated to assist
traditional chemotherapy by enhancing the immune responses in mouse experimental models
(Figure 2) [67,68]. This finding is supported by the demonstration that the aerosolization of
bacteria isolated from lung microbiota of antibiotic-treated mice reduces lung metastasis implan-
tation by enhancing cancer immune response [60]. This study also showed that lung microbiota
might be manipulated by antibiotic or probiotic aerosolization, and those changes are associated
with a reversion of immunosuppression present in the tumor microenvironment (Figure 2), favor-
ing the immune response against cancer cells. In addition, this treatment increased the activation
of the antitumoral NK and T cell response and the maturation of resident antigen-presenting cells
(APCs), correlating with a reduction of protumoral M2 macrophages and Treg cells [60]. It
was also found that after the shift from Firmicutes to Proteobacteria as the main Gram-negative
bacterial species, two ubiquitous opportunistic pathogens from the Proteobacteria phylum,
Morganella morganii and Escherichia fergusonii, exerted an immunostimulatory effect through
the production of different virulence factors [60]. These results confirm the key role of lung
bacteria in the antitumor immune response and advocate that a balance among different bacterial
species is crucial for antitumor immune responses. Importantly, they support the use of aerosol-
ization with probiotics or antibiotics as a clinical therapeutic procedure to improve patient
outcome [60].
Microbiota and Cancer Immunotherapy
Most experimental studies analyzing the role of microbiota in the efficacy of immunotherapy have
been focused on gut microbiota, indicating that specific bacterial taxa are associated with theTrends in Cancer, Month 2020, Vol. xx, No. xx 9
Outstanding Questions
What is the best method to analyze the
lung microbiome?
How andwhen does the lungmicrobiota
affect lung cancer development?
Are there oncobacterial strains capable of
producing substances with oncogenic
properties?
How does the host immunity–bacteria
interaction boost cancer development?
Could the lung microbiota profile be
used as a predictive biomarker for risk
of lung cancer development and/or
for patient outcome (response and/or
toxicity) during immunotherapy?
What bacterial taxa may have a
beneficial and/or detrimental effect on
lung carcinogenesis?
Could specific lung commensal bacteria
be modulated to prevent lung cancer
development?
Could the lung microbiota be modulated
to improve response and reduce toxicity
in lung cancer patients treated with
immunomodulatory agents?
Trends in Cancerantitumoral effect of ICIs, anti-CTLA4, and anti-PD-1/L1 [3–5,67] or with the efficacy of
cyclophosphamide in lung cancer patients [68]. One of those studies showed that patients
treated with antibiotics early before, during, or shortly after treatment with ICIs significantly
decreased their efficiency against advanced epithelial cancers, including lung cancer [3]. Although
this study was focused on changes in gut microbiota during antibiotic treatment, it is expected
that those changes also affect lung microbiota and, thus, might modulate the local immune
response against lung carcinoma. However, this assumption should be experimentally validated.
Derosa et al. also showed that previous antibiotic treatment was associated with worse
outcomes in NSCLC patients treated with ICIs, although changes in lung microbiota were not
analyzed [69].
Concluding Remarks
Lung cancer is the leading cause of cancer deaths worldwide and while smoking and chronic
obstructive pulmonary disease (COPD)/emphysema is a well-established risk factor for lung
cancer, only a small percentage of these patients develop lung cancer. Evidence now supports
that the lung microbiota may play a key role in carcinogenesis and in the response to chemother-
apy and immunotherapy (Figure 2). Even though airway microbiota are clearly low in terms of
biomass when compared with gut microbiota, we should not underestimate the potential signif-
icance of these local host–microbe interactions. Several studies have recently reported a correla-
tion between specific components of lung microbiota, lung carcinogenesis and metastasis, and
the lung immune response. These interactions include the modulation of chronic tumorigenic
inflammatory responses, the appearance of genetic alterations driven by specific bacterial
components and the generation of defective local immune responses.
Recent studies have shown that the composition of gut microbiota influences the cancer immune
response and the efficacy of ICIs in different types of cancer. However, it is still dependent on
experimental validation if, as expected, the composition of lung microbiota also regulates the
efficacy of ICI immunotherapy in lung cancer patients (Figure 2, see Outstanding Questions).
This hypothesis is supported by evidence from studies including lung cancer patients treated
with antibiotics and ICIs, and the correlation between lung microbiota composition and lung
immune responses. However, it should be pointed out that the effect of antibiotics observed in
gut microbiota might be different to those observed in lung microbiota, in light of the intrinsic
physiological differences of both tissues. In addition, we do not yet know if, as in the case of
gut inflammatory toxicity observed during ICI immunotherapy, lung inflammatory pneumonitis
observed during ICI treatment also depends on the presence of specific microorganisms in the
lungs (see Outstanding Questions).
Proper analyses correlating lung bacterial microbiota composition, antibiotic treatment and/or ICI
efficacy, and toxicity will be required to reach this conclusion (see Outstanding Questions) and
support the use of therapeutic approaches such as antibiotics or aerosolized microbial composi-
tions, to modulate lung microbiota and improve the treatment of lung cancer.
Once we confirm all these hypotheses, new challenges will require further optimization, such as
monitoring the length and degree of dysbiosis, that will depend on antibiotic nature and presence
of resistant bacteria, which will dictate the timing and composition of microbiota recolonization
(see Outstanding Questions).
Last but not least, due to the general use of NGS directed against 16S, most studies have
focused on the bacterial component of microbiota. However, it is expected that other microbial
communities such as fungi and viruses might also influence the lung carcinogenic process as10 Trends in Cancer, Month 2020, Vol. xx, No. xx
Trends in Cancerwell as the natural and pharmacological modulation of the immune response in lung carcinoma
(see Outstanding Questions). All these studies will require time and effort but the final goal
deserves it.References
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